Plasmacure has developed PLASOMA, a medical device that applies bactericidal cold plasma directly to chronic wounds, significantly enhancing the healing process. Clinical studies show that PLASOMA is 2.5 times more effective than standard care, reducing healthcare costs by over 40% and minimizing patient visits by more than 50%.
Funding
$1.3M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Chronic wounds, particularly diabetic foot ulcers, pose a significant healthcare challenge, often leading to amputations and high treatment costs. Standard wound care methods can be slow and ineffective, resulting in prolonged patient suffering and increased healthcare resource utilization.
Solution
Plasmacure's PLASOMA device delivers bactericidal cold plasma directly to chronic wounds to accelerate healing. The device applies a patented cold plasma solution directly to the wound site, stimulating the healing process. Clinical studies have demonstrated that PLASOMA is significantly more effective than standard care, leading to faster wound closure, reduced healthcare costs, and fewer patient visits. The technology offers a potential solution to improve patient outcomes and alleviate the burden of chronic wound management on healthcare systems.
Target Audience
The primary target audience includes healthcare providers, wound care specialists, hospitals, and clinics involved in the treatment of chronic wounds, particularly diabetic foot ulcers.
Features
- Direct application of bactericidal cold plasma to the wound
- Patented technology for safe and effective plasma delivery
- Enhanced wound healing compared to standard of care
- Reduction in healthcare costs associated with chronic wound management
- Fewer required patient visits due to accelerated healing